A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

ClinicalTrials.gov ID: NCT00817986

Public ClinicalTrials.gov record NCT00817986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.

Study identification

NCT ID: NCT00817986
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: XenoPort, Inc.; Industry
Enrollment: 161 participants

Conditions and interventions

Conditions

Back Pain

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2008 (Type not available)
Primary completion: Jul 2009 (Actual)
Completion: Jul 2009 (Actual)
Last update posted: Feb 21, 2021

2008 – 2009

United States locations

U.S. sites: 20
U.S. states: 13
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Litchfield Park	Arizona	85340	—
Not listed	Anaheim	California	92084	—
Not listed	Anaheim	California	92801	—
Not listed	San Diego	California	92128	—
Not listed	Vista	California	92083	—
Not listed	Fort Lauderdale	Florida	33306	—
Not listed	Miami	Florida	33143	—
Not listed	Atlanta	Georgia	30308	—
Not listed	Overland Park	Kansas	66211	—
Not listed	Erlanger	Kentucky	41018	—
Not listed	Traverse City	Michigan	49684	—
Not listed	Brick	New Jersey	07732	—
Not listed	Raleigh	North Carolina	27612	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Oklahoma City	Oklahoma	73122	—
Not listed	Anderson	South Carolina	29621	—
Not listed	Dallas	Texas	75234	—
Not listed	Houston	Texas	77074	—
Not listed	San Antonio	Texas	78215	—
Not listed	Salt Lake City	Utah	84106	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00817986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 21, 2021 · Synced Oct 28, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00817986 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →